Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
HNGE proposed sale of 781 shares of Common Stock. The Form 144 lists 781 shares to be sold pursuant to an Employee Stock Purchase Plan on 05/15/2026 for cash through Morgan Stanley Smith Barney LLC. The filing also discloses recent 10b5-1 sales by James Budge on 02/23/2026 (14,763 shares, $580,736.79), 03/23/2026 (11,006 shares, $465,138.87), and 05/11/2026 (5,906 shares, $323,758.65).
Hinge Health, Inc. President James Pursley received a grant of 65,000 shares of Class A Common Stock on April 29, 2026 through a restricted stock unit (RSU) award. The RSUs were granted for no cash consideration and each RSU converts into one share upon vesting. Following this award, Pursley directly holds 795,442 shares of Class A Common Stock reported in this filing.
Hinge Health, Inc. reported that Chief Financial Officer James Budge received an award of 65,000 shares of Class A Common Stock in the form of restricted stock units. The RSU grant was acquired for no cash consideration and brings his directly held stake to 451,293 shares.
Hinge Health, Inc. Chief Financial Officer James Budge sold 5,906 shares of Class A Common Stock in open-market transactions. The sales occurred on May 11, 2026 at weighted average prices of $55.48 and $54.65 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he continued to hold 386,293 shares directly, indicating that the trades represent a small portion of his overall stake.
Hinge Health, Inc. disclosed that investment funds affiliated with Bessemer Venture Partners sold Class A Common Stock in open-market transactions. On May 7, 2026, Bessemer Venture Partners X L.P. sold 154,740 shares and Bessemer Venture Partners X Institutional L.P. sold 145,260 shares at a weighted average price of $54.77 per share, in multiple trades between $54.10 and $55.00. On May 8, 2026, the same funds sold 103,160 and 96,840 shares, respectively, at a weighted average price of $55.16, with trade prices ranging from $55.04 to $56.02. Reporting person Robinson Elliott, a partner at Bessemer Venture Partners, has an indirect, passive economic interest in these holdings and disclaims beneficial ownership except to the extent of any pecuniary interest.
HNGE affiliate filed a Form 144 to sell restricted stock units and reports recent 10b5-1 sales. The filing lists 5,906 Restricted Stock Units with an effective date of 04/01/2026. It also discloses two 10b5-1 dispositions in the past three months: 14,763 shares on 02/23/2026 and 11,006 shares on 03/23/2026, with aggregate cash amounts shown for those sales. The notice is a routine affiliate sale filing under Form 144.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported converting and selling shares of the company’s stock. On May 6, 2026, he converted 50,000 shares of Class B Common Stock into Class A Common Stock and then sold 50,000 Class A shares in open-market transactions at a weighted average price of $55.0087 per share, with individual prices ranging from $55.00 to $55.05. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, he reported no directly held Class A shares, while continuing to hold Class B shares indirectly through a family trust and a Grantor Retained Annuity Trust that are convertible into Class A stock.
Hinge Health, Inc. director and CEO & Co-Founder Daniel Antonio Perez reported insider transactions involving Class A and Class B Common Stock. Through an account noted as held "By Spouse," he sold 150,000 shares of Class A Common Stock on May 6 and May 7, 2026 in open-market transactions at weighted average prices of $55.0884 and $55.0503 per share, respectively, under a Rule 10b5-1 trading plan adopted with his spouse on September 11, 2025.
The sales were paired with conversions of an equivalent number of Class B Common Stock into Class A Common Stock. After these indirect transactions, his spouse’s account held 35,470 Class A shares and 358,445 Class B shares. Separately, Perez directly held Class B Common Stock that was convertible into 9,488,845 Class A shares, showing he retains a substantial equity position despite the pre-planned sales.
Hinge Health, Inc. reported strong first-quarter 2026 results, with revenue of $182.3 million, up from $123.8 million a year earlier, driven by its AI-powered musculoskeletal care platform.
Net income rose to $35.1 million from $17.1 million, and diluted earnings per share were $0.41. Operating cash flow improved to $43.1 million from $4.9 million, supporting a significant capital return: the company repurchased and cancelled 2.45 million Class A shares for $105.8 million under its $250 million buyback program, leaving $80.0 million authorized for future repurchases.
The balance sheet showed total assets of $728.8 million, including $186.7 million of cash and cash equivalents and $219.0 million of marketable securities, alongside deferred revenue of $340.8 million that reflects future subscription obligations. Hinge Health continues to invest heavily in growth, with research and development, sales and marketing, and general and administrative expenses totaling $122.2 million, and recorded $11.7 million of stock-based compensation as it scales its workforce and technology.
HNGE filed Form 144 reporting sales of Class A shares by Bessemer Venture Partners entities. The notices list multiple transactions in February 2026. Examples include Bessemer Venture Partners X LP selling 77,328 shares on 02/13/2026 and Bessemer Venture Partners X Institutional LP selling 72,591 shares on 02/13/2026.